

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNITED GENE HIGH-TECH GROUP LIMITED

聯合基因科技集團有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

APPOINTMENT OF EXECUTIVE DIRECTOR

This announcement is made by United Gene High-Tech Group Limited (the “**Company**”) pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company is pleased to announce the appointment of Mr. Tang Rong (“**Mr. Tang**”) as an executive director of the Company with effect from 29 September 2014.

The biographical details of Mr. Tang Rong are set out as follows:

Mr. Tang Rong, aged 47, graduated from Fudan University in the People’s Republic of China in July 1989 with a bachelor’s degree in science, majoring in genetics and genetic engineering. He has been a genetic engineer of The Institute of Genetics of Fudan University from August 1989 and has extensive experience in genetics related technology development, commercialization and market development. Mr. Tang obtained several patents in China and published papers in many science magazines in genetics related subjects. He was invited as the member of the Committee of Experts of 上海聯眾基因科技研究院 (Shanghai Lianzhong Institute of Gene Technology) in 2000. Starting from November 2010, Mr. Tang was appointed as the Director of Gene Testing Research and Development Department of Longmark (Shanghai) Healthcare Limited and he has professional expertise in gene testing and research & development.

Mr. Tang held no other directorship in any listed public company in the last three years preceding the date of his appointment. Further, Mr. Tang does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

As at the date of this announcement, Mr. Tang held 396,200 shares of the Company. Save as disclosed, Mr. Tang does not have any interest (within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) in the securities of the Company.

Mr. Tang has entered into a service contract with the Company for a fixed term of three years starting from 29 September 2014. He will hold the office until the next annual general meeting of the Company and is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the bye-laws of the Company. Mr. Tang will be entitled to a salary of HK\$37,500 per calendar month, and that he will also be entitled to receive 13 months' salary per year in addition to a directors' fee of HK\$60,000 per year, which was determined by the Board with reference to his experience, duties and responsibilities in the Company as well as the current market rate.

Save as disclosed in this announcement, Mr. Tang has not been involved in any of the events under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters in relation to his appointment as an executive director that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board would like to express its warm welcome to Mr. Tang for joining the Board.

By Order of the Board
United Gene High-Tech Group Limited
Lee Nga Yan
Executive Director

Hong Kong, 26 September 2014

As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Ms. Lee Nga Yan (executive Director), Dr. Guo Yi (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).